Substack · Jota Investor
IOVA: ¿Humo o realidad? Parte 1
Investigación de Iovance Biotherapeutics a fondo
Since publication +71.0% α +70.7 pp vs S&P 500 · USD
US · 1 entry · 1 publication
Iovance Biotherapeutics, Inc.
No entry states a stance.
Free during launch: log in or sign up with your email to see it.
Sign up freeSubstack · Jota Investor
Investigación de Iovance Biotherapeutics a fondo
Since publication +71.0% α +70.7 pp vs S&P 500 · USD
Prices as of the Oct 27, 2026 close. Past performance does not guarantee future results. Price-only, excluding dividends, in local currency. Data may be delayed or inaccurate. Not investment advice. How it is calculated.